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Traditional medicines, derived from plants, could present alternative treatment strategy for cancer therapy. One such plant is Momordica charantia 
(MC) which possesses anti-carcinogenic properties. This study investigated the anticancer effect of an ethanol extract of MC fruit, Kuguacin-J (K-J), an 
isolated compound from the leaves of MC and cisplatin, either alone or combination on healthy MCF-10A mammary cells and compared with breast 
cancer MCF-7 and MDAMB-231 cell lines. Cell viability was tested using 8 μg/mL and 80 μg/mL doses of MC extract, K-J and cisplatin individually or 
combined for 24 and 48 hours. Caspase-3- activity was measured in MCF-7 and MDA-MB-231 cells using established methods. The results revealed 
that MC extract and K-J had no effect on healthy MCF-10A cell viability as compared to cisplatin which induced dose and time-dependent cell death. 
Similarly, treatment of MCF-7 cells with cisplatin induced cell death at high concentration at both the time points, while MC extract and K-J only induce 
MCF-7 cell death at high dose after 48 hours only. During combination therapy, both doses of cisplatin enhanced MCF-7 cell death when combined 
with MC extract or K-J after 24 and 48 hours. In MDAMB-231 cells, the three drugs, either alone or combined, evoked significant cell death at both the 
doses and time points. All three drugs, at high dose, elicited significant increase in caspase-3- activity in MCF-7 and MDA-MB-231 cells as compared 
to untreated cells. The results revealed that either MC extract or K-J alone or combined with cisplatin, can elicit significant increase in cell death and 
caspase–3-activity in MCF-7 and MDA-MB-231cells as compared to untreated cells.
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     Graphical Abstract
Introduction
Breast cancer (BC) continues to be an increasing major 
public health problem worldwide and more so, it remains 
a significant scientific and communal challenge. Globally, 
breast cancer is the most frequently diagnosed cancer 
in women, with an estimated 19.3 million new cases 
and 10 million deaths annually worldwide making it the 
most common cause of female cancer death in both the 
developed and developing counties [1]. Breast cancer is 
the most common cancer in the UK, accounting for 54,722 
(15%) of all new cancer cases for women in 2017 (99% of 
breast cancer cases in the UK are in females and 1% are 
in males) [2]. For females, breast cancer European age-
standardized incidence rates in the UK increased by 23% 
between 1993-1995 and 2015-2017. For males, breast 
cancer age-standard incidence rates in the UK remained 
stable between 1993-1995 and 2015-2017. Alarmingly, 
based on current projections, these figures are expected 
to triple by 2040 due to an ageing population, continued 
improvements in survival and of great concern from an 
economic point of view [3]. Recent research indicates that 
the annual burden of breast cancer to the UK economy is 
£1.5bn, while in the USA, it is estimated at $19.7bn [4].
Despite substantial advances that have been made in the 
treatment of breast cancer, introduction of methods to 
predict which group of women are at elevated risk and 
prevention of the disease have been less successful. The 
incidence is rising in most countries and is projected to 
increase further over the next 20 years despite current 
efforts to prevent the disease [5-7].
Abbreviations:
K-J  Kuguacin-J
BC  breast cancer
M. charantia Momordica. charantia
MC  Momordica. charantia
HRT  hormone replacement therapy
BRCA1 and BRCA2 breast cancer 1 and breast cancer 2
FBS   Fetal bovine serum
ICPMS   Inductively coupled plasma mass spectrometry
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BC is caused by many risk factors including obesity, 
alcohol consumption, inactivity, genetics, lowering age of 
menarche, late age of first pregnancy, fewer pregnancies, 
shorter or no periods of breast-feeding, a later menopause 
and hormone replacement therapy (HRT) and others [8]. 
Previous studies have shown that the impact of hereditary 
breast cancer has increased [9] with birth cohort effects 
seen for both breast cancer 1 (BRCA1) and breast cancer 2 
(BRCA2) [10] and the data also suggest that both familial 
and non-familial risks have increased.
At present, the primary forms of treatment of cancer include 
surgery, radiation therapy, and systemic treatment, 
including chemotherapy, targeted therapy, hormonal 
therapy, and immunotherapy. Throughout the last half-
century, cancer treatment has been characterized by highs 
and lows, due to the side effects, the ineffectiveness of 
treatment and the failed hope of complete remission and 
cure. Among the therapeutic arsenal, alongside surgery in 
the case of solid tumors, antitumor drugs and radiation 
have been the treatment of choice in many instances [11]. 
Among many chemotherapy drugs that are widely used 
for cancer, cisplatin is one of the most compelling ones. 
It was the first FDA-approved platinum compound for 
cancer treatment in 1978 [11]. Platinum responsiveness is 
high primarily, but many cancer patients will ultimately 
relapse with cisplatin-resistant disease. Hence, drug 
resistance has been observed in many patients who have 
relapsed from cisplatin treatment and more so the drug 
can also induce side effects [12].
As opposed to classic alkylating agents, cisplatin 
binds with DNA to form intra-strand crosslinks and 
adducts that cause changes in the conformation of the 
DNA and affect DNA replication. Other mechanisms of 
cisplatin cytotoxicity include mitochondrial damage, 
decreased ATPase activity, and altered cellular transport 
mechanisms. Published research studies have implicated 
DNA as a critical target for cisplatin cytotoxicity, the most 
revealing evidence being the hypersensitivity to cisplatin 
by both prokaryotic and eukaryotic cells deficient in DNA 
repair [12, 13].
With the aforementioned cytotoxic side effects of this and 
other commercial antitumor drugs, it is of paramount 
importance to develop alternative therapies which can 
be applied either alone or in combination with other 
components to treat BC. Recently, immunotherapy 
has become an essential therapeutic alternative, and 
even nanotechnology has recently arrived on the scene, 
offering nanostructures as new therapeutic alternatives. 
However, side effects and remission persist [14].
One such alternative that has been used for many years 
to treat cancer and other diseases is plant-based extracts. 
Research has shown that the plant, Momordica charantia 
(M.charantia or MC) (Family: Cucurbitaceae) has been 
used as traditional medicine since ancient times for its 
various medicinal properties [15]. Several studies have 
conducted extensive research and published research 
and review papers on the extract of this plant and its 
components obtained from its fruits, seeds, leaves and 
stem [16-20].
The medicinal benefits of MC lie in the bioactive 
phytochemical components. These constitute chemicals 
which help to generate physiological effects on the human 
immune system, protecting it from various diseases. Of the 
many compounds that have been identified and isolated 
from MC, most of these falls under the groups of proteins 
and triterpenes. We have published a detailed review of 
MC and its isolated bioactive compounds [18], among one 
compound which have shown strong biological activities is 
cucurbitacins, a group of cucurbitane-type triterpenoids. 
Today, more than 50 triterpenoids have been isolated 
from MC including Kuguacin J (K-J), a triterpenoid 
isolated from the leaves of Momordica charantia which 
have demonstrated apoptosis in androgen-dependent 
human prostate cancer [20, 21]. The present study focused 
on the in vitro effects of an ethanol extract of the green 
fruit of MC, K-J, a purified component of MC leaf extract 
and cisplatin, a commercial established anticancer drug, 
either alone or in combination on two different human 
breasts cancer cell lines, estrogen receptor ER-positive 
and progesterone receptor (PR)-positive MCF-7 and 
triple-negative MDBMB-231 cells and compared to 
healthy control MCF-10A breast cells. The rationale was 
to ascertain if a low dose of cisplatin combined with high 
doses of either the MC ethanol soluble extract or K-J can 
exert maximal effect in cell death without killing healthy 
cells in the body.
The main objective of this study was to find a natural 
product approach using plant-based medicine to treat 
TNBC. MDA-MB-231 is a highly aggressive, invasive 
and poorly differentiated triple-negative breast cancer 
(TNBC) cell line as it lacks ER and PR expression, as well 
as HER2 (human epidermal growth factor receptor 2) 
amplification were used in this study.
Materials and Method
Materials and cell lines
M. charantia was purchased fresh from local supermarket. 
Ethanol was purchased from Fisher Scientific. MCF-10A 
normal cell line (healthy) was maintained in Mammary 
Epithelial Cell Growth Medium and with passage 39-100. 
MCF-7 (breast adenocarcinoma cell lines) was maintained 
in Dulbecco’s Modified Eagle’s medium supplemented 
with 10% FBS and passage 40. Similarly, MDAMB-231 
(Triple negative resistance breast cancer cell lines) were 
conducted with passage range from 40-56 in Dulbecco’s 
Modified Eagle’s medium (DMEM) supplemented with 
10% Fetal bovine serum (FBS). MDAMB-231 line was 
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purchased from Public Health, UK while all the media 
were purchased from Gibco (Thermo Fisher, Scientific, 
Waltham, MA, USA).
Preparation of M. charantia plant ethanol extract
The unripe green fruits of M. charantia were obtained from 
the local market and subsequently cleaned of internal 
tissues and cut into small pieces [22]. Approximately one 
kilogram of chopped green fruit was liquidized in 70% 
ethanol for 5-10 min using a blender at room temperature. 
The ethanol sample was poured into a 2L bottle and 
capped. The bottle was then kept at room temperature 
for 6-8 weeks and mixed daily by shaking periodically. 
It was then filtered through Whatman filter paper (No: 
4 Whatman, UK) to remove any residue. The filtered 
brown ethanol sample was then transferred to the 1000 
mL round bottom rotating flask (Figure 1A). The flask was 
then connected to the Rota-evaporator machine through 
a clamp. The rotating flask was then heated by partial 
emersion in a hot water bath at a temperature of 40°C. 
A typical 120 rpm speed was used for the flask rotation. 
The rotary-evaporated sample was then scrapped using 
spatula and dried overnight in an oven at 43°C. This crude 
ethanol soluble extract was stored at 2-5°C for further use 
(Figure 1B).
Measurement of cytotoxicity effect of MC alcohol-
soluble extract, K-J and cisplatin on the MCF-7 and 
MDAMB 231 breast cancer and MCF-10A healthy 
control cell lines using Presto-Blue Assay
An amount of 30 mg of the crude alcohol-soluble extract 
of M. charantia was initially dissolved in 100 μl DMSO by 
continuous stirring and with the brief use of a sonicator 
water bath. This was made up to 5 mL by adding 4.5 mL of 
the cell medium. The alcohol-soluble crude extract stock 
solution was filtered using 0.22 μm sterile filters. These 
stock solutions were stored in a sealed tube at 2-5°C 
(fridge) until required. Once removed from the fridge 
(2-5°C), the prepared alcohol-soluble extract of M. 
charantia solutions were gently warmed in a water bath at 
37°C in order to ensure that the MC ethanol soluble extract 
was mixed complete in solution, before aliquoting into 
the concentrations of 8 μg/mL and 80 μg/mL. Similarly, 
either K-J or cisplatin was weighed and dissolved in 100 
μl DMSO and then diluted in the incubating medium at 
concentrations of 8 μl/mL and 80 μl/mL. The two different 
concentrations of the MC alcohol soluble extract in cell 
medium were transferred in triplicate using a Gilson 
pipette to 96 well plates to give a final volume of 200 μl 
to the treated cell wells. An equivalent volume of 200 μl 
of the medium was added to the control (untreated) well 
with cells. For combination treatment, cisplatin (either 8 
μg/mL or 80 μg/mL) was combined with either the alcohol 
soluble extract or K-J using either 8 μl/mL or 80 μl/mL. In 
this study, both time and dose-dependent experiments 
were performed either with each drug individually or 
during combination compared to control experiments 
without either drug for comparison. The time-dependent 
experiments were done initially over a period of 24 and 
48 hours to ascertain the time that produced maximal cell 
death. Once the times of cell death were established, both 
time-and dose-dependent experiments were performed 
during the incubation period of 24 and 48 hours either 
alone or when combined. At the end of the treatment with 
either the MC alcohol soluble extract, K-J or cisplatin, 
the fluorescence was determined using Tecan-microtiter 
plate reader at excitation 570 nm and emission 610 nm [22]. 
Control experiments were also done using DMSO alone 
in the media which contained cells. The results showed 
that DMSO had no effect on cell death. The percentage 
cell viability (cell death) was calculated compared to the 
control subtracting the background reference employing 
the following equation:
Measurements of caspase-3 activity in untreated 
and treated MCF-7 and MDAMB-231 breast cancer 
cell lines with either the MC ethanol extract, K-J or 
cisplatin
The two different breast cancer cells lines were incubated 
with 80 μg/mL of either crude water-soluble extract of 
M. charantia or K-J. The induced apoptosis cell suspension 
contained roughly 107 cells. A sample of non-induced 
cells for a zero-time (control) also contained 107 cells. 
The induced and non-induced cells were incubated for 
48 h at 37°C in 5% CO2 atmosphere. The induced cells 
and the control cells were transferred to 15 ml centrifuge 
tube and centrifugation at 600 x g for 5 min at 2-5°C. The 
supernatant was removed by gentle aspiration for both 
induced and control cell suspensions. The cells were then 
pelleted and washed once with 1 ml of phosphate buffer 
solution and centrifuged at 5000 rpm for 5 min and the 
supernatant was completely removed by gentle aspiration. 
The centrifuged cell pellets were then treated with 1 X lysis 
buffer at a concentration of 100 μl per 107 cells, and the 
cells were incubated on ice for 15-20 min. The lysed cells 
were centrifuged at 16,000 to 20,000 x g for 10 to 15 min 
at 2-5 °C and the supernatants were transferred to new 
1 ml tube and subsequently frozen in liquid nitrogen and 
stored in aliquots at -70°C for further use (All the values 
were expressed as μmoL/min/mL (Table 1).
Analysis of M. charantia for some of its contents
The green fruit of M. charantia was dried and pulverized 
into a powder and a known amount was dissolved in either 
deionized water or 70% ethanol for chemical analysis. 
These soluble samples were used to measure cation 
concentrations using ICPMS technique while antioxidant 
activity, vitamin–c, total protein, phenolic and 
antioxidant contents were measured by well- established 
biochemical methods [23, 24].
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All control and test data collected from the different 
experiments were analyzed using Student’s t -test 
and ANOVA test via PRISM Graph-Pad software for 
comparison. Data obtained were expressed as mean ± 
standard deviation (S.D). All experiments were performed 
in triplicate (n=3). A value of (p < 0.05) was taken as a 
significant result.
Results
Cytotoxicity of MC extract, K-J and cisplatin either 
alone or in combination
The MCF10A human mammary epithelial cell line is a 
widely used in vitro model for studying normal breast 
cell function and transformation. Figure 2 shows light 
microscope morphological images of MCF-10A cells 
(A) without any drug treatment (control) and following 
treatment with 8 μg/mL of either (B) the alcohol soluble 
extract of M. charantia, (C) K-J or (D) cisplatin. These 
initial morphological studies have shown that the alcohol 
soluble extract and K-J, using 8 μg/mL, had little or no 
effect on the viability of healthy MCF-10A cell line as 
compared to cisplatin which reduced cell viability causing 
cell death.
The data from three different experiments in Fig 2, 
using two different doses, were quantified and presented 
graphically as bar charts in Fig 3 for comparison. The 
results show that at low and high doses (8 μg/mL and 
80 μg/mL), MC ethanol extract either alone or when 
combined with cisplatin had no significant (p>0.05) 
effect on the viability of healthy MCF-10A cell line at 
24 and 48 hours of incubation (Fig 3A-D). On the other 
hand, K-J, a purified single anticancer compound from 
M.charantia, also had no effect on MCF-10A cell line 
at low dose of 8 ug/mL either alone or in combination 
with high and low doses of cisplatin after 24 hours of 
incubation (Fig 3A/B). When the dose of K-J was increased 
to 80 ug/mL, it killed MCF-7 cells significantly (P<0.001) 
compared to untreated cells (Fig 3C). On the other hand, 
cisplatin, at both low and high doses (8 μg/mL and 80 
μg/mL), killed MCF-10A cells significantly (p<0.001) as 
compared to untreated (control) cells at both 24 and 48 
hours of incubation (Fig 3A/C). Surprisingly, when K-J 
at a high dose was combined with either a low and a high 
dose of cisplatin, it had no significant (p>0.05) effect on 
cell viability compared to untreated (control) cells (Fig 
2B/D). These findings indicate that MC ethanol extract is 
safe to use in breast cancer therapy either alone or when 
combined with cisplatin. On the other hand, K-J alone at 
a high dose seems to be less safe just like cisplatin since 
both can kill healthy breast cells.
Figure 4 shows the concentration-dependent cytotoxicity 
effect of either MC alcohol extract, K-J or cisplatin on 
MCF-7 breast cancer cells employing a separate (either 8 
μg/mL or high 80 μg/mL) dose and combination treatment 
with either low or high dose (8 μg/mL or high 80 μg/mL) 
of cisplatin with MC ethanol extract or K-J for 24 hours 
and 48 hours of treatment. The results show that at a low 
dose, all three compounds had no effect on cell viability 
after 24 hours of treatment. However, when the cells were 
treated with a higher dose (80 μg/mL) of either of the three 
compounds for 24 hours, only cisplatin killed the cells 
significantly (p<0.005) compared to untreated (control) 
cells (Fig 3A). During combination treatment for 24 hours, 
employing a low dose (8 μg/mL) of cisplatin with a high 
dose (80 μg/mL) of either MC ethanol extract or K-J, cell 
viability reduced by around 25%. However, when the dose 
of cisplatin was increased to 80 μg/mL and combined with 
8 μg/mL of either the ethanol extract or K-J, cell death 
increased by about 25% after 24 hours of treatment. In 
contrast, when the dose of all the three compounds was 
increased to 80 μg/mL, there was significant (p<0.001) 
increase in cell death (decreased cell viability) for both K-J 
and MC ethanol extract after 24 hours which was more or 
less similar to the effect of cisplatin alone (Fig 2B).
Incubation of MCF-7 breast cancer cell line for 48 
hours with 8 μg/mL with either compound individually 
resulted is a small, but significant (p<0.05) increase 
in cell death as compared to untreated (control) cells. 
When the concentration was increase to 80 μg/mL, both 
the MC ethanol extract and cisplatin killed MCF-7 cells 
significantly (p<0.001) compared to untreated cells 
(Fig 3C). During combination treatments, cisplatin at 
either 8 μg/mL or 80 μg/mL was able to kill MCF-7 cells 
significantly (p<0.001) when incubated with either low (8 
μg/mL) or high (80 μg/mL) of the MC ethanol extract or 
K-J (Fig 3D). These finding support the hypothesis that 
combined application is a safer option for breast cancer 
therapy using a low dose of cisplatin with a high dose of 
MC ethanol extract or K-J for 48 hours of treatment.
Fig 5 shows the dose-dependent cytotoxicity effect of 
either MC ethanol extract, K-J or cisplatin on MDA-MB-
231-triple negative cell line employing individual and 
combined doses for comparison following 24 hours and 
48 hours of treatments. Compared to MCF-7 breast cancer 
cells, the results presented in Fig 5A-D clearly show that 
either MC ethanol extract, K-J or cisplatin were highly 
effective, either alone or in combination, in killing MDA-
MB-231-triple negative breast cancer cells significantly 
(p<0.001) compared to untreated (control) cells at all 
doses and treatment times employed in this study. These 
results demonstrated that either the MC alcohol soluble 
extract, K-J or cisplatin either alone or in combination at a 
low dose of 8 μg/mL was as effective as a high dose 80 μg/
mL in killing MDA-MB-231 breast cancer cells, making 
the MC ethanol extract a very safe treatment option for 
triple negative breast cancer.
Anticancer effect of M. charantia
Houacine C, Singh J, Singh R, Jeeboo K, Ansari AA, et al. The Cytotoxic effect of an Ethanol extract of Momordica Charantia, Kuguacin-J and Cisplatin on 
healthy MCF-10A and MCF-7 and MDAMB-231 breast cancer cell lines employing In Vitro assays. G Med Sci. 2021; 2(4): 016-029.
https://www.doi.org/10.46766/thegms.pharma.21062806
21
Measurement of caspase -3 activity
There are a number of subcellular, cellular, molecular and 
structural mechanisms whereby anti-cancer drugs can 
induce cell death including apoptosis, autophagy, necrosis, 
microtubule disassembling, DNA damage, mitochondrial 
cytochrome release and calcium over-loading as well as 
others. In some cases, more than one processes occur, and 
however it is well known that apoptosis is the dominant 
type involving the formation of multi-protein complexes 
that provide the molecular scaffolding for the activation 
of the initiator caspases including caspase -8 (extrinsic 
pathway), caspase -9 (intrinsic pathway) and caspase -3 
(executioner caspase caspase-3 pathway) [25, 26].
Since the MC ethanol extract, K-J and cisplatin can 
induce cell death of both MCF-7 and MDA-MB-231-
triple negative cell lines, it was relevant to investigate 
the cellular mechanism(s) or pathway(s) involved in 
cell death. Caspase-3 activity was investigated on using 
caspase-3 calorimetric kit reading the absorbance using 
Tecan plate reader. Caspase activity was observed after 
treating the cells with a dose of 80 μg/mL for 48 hours. 
The amount of protein released during the assay was 
quantified and used to determine the caspase activity. The 
results are presented in figure 6 and they show that MC 
ethanol extract, K-J and cisplatin can elicit significant 
(p<0.05) increase (two-fold) in caspase-3 release 
(enhanced activity) in both MCF-7 and MDAMB-231 cell 
lines as compared to control after 48 hours of treatment. 
Surprisingly, there was significant difference (p<0.05) 
between the activity of caspase-3 produced by MC ethanol 
extract, K-J and cisplatin. Typically, in both MDAMB-231 
and MCF-7cell lines the MC ethanol extract, K-J and 
cisplatin increased caspase-3 activity by 82, 75 and 76%, 
respectively, indicating that all three agents are inducing 
cancer cell death through the activation of the caspase-3 
pathway.
Chemical contents of M. charantia
Following chemical analysis, the results show that 
the fruit is rich in proteins (2.86+0.07 %), vitamin C 
(125+1.75mg/100 g), carotenoid (1.09+0.06 mg/100 g), 
phenolic content (2.42+0.25 mg/100 g), anti-oxidant 
activity dry weight (44.5+2.46%), including the presence 
of caffeic (221 ng/g) and celuic acid (623.6 ng/g) and a 
number of cations including sodium (7.76+0.51 mg/g), 
potassium (0.667+0.044 mg/g), calcium 28.95+2.21 
mg/g), magnesium (0.443+0.0028 mg/g), manganese 
(0.42+0.03 mg/g), copper (0.26+0.031 mg/g) and zinc 
(0.99+0.03 mg/g). Among the cations, the fruit had 
significantly (p<0.05) more sodium and calcium compared 
to the other cations present.
Discussion
Globally, breast cancer (BC) is the most common cancer 
in women with the most recent published statistics 
indicating 19.3 million new cases in 2021, second only 
to lung cancer, which corresponds to 11.6% of all new 
cancer cases. Research has shown that breast cancer was 
responsible for 10 million deaths in 2021, representing 
6.6% of cancer deaths [1].
Sadly, it is estimated that these values will continue 
to increase as it is estimated that by 2050, the yearly 
incidence of BC will reach around 3.2 million [27]. BC 
is caused by many risk factors including age, obesity, 
radiation, genetic disposition, family history of the disease 
which may link to inherited genes, excess alcohol intake, 
lack of exercise, hormone replacement therapy (HRT), 
personal history of BC, race/ethnicity, menstrual, breast-
feeding and pregnancy history, dense breast, exposure to 
environmental factors, chemicals, drugs and many others 
[28, 29]. BC can be easily prevented by eating a balanced 
diet, exercising regularly and reducing alcohol intake and 
avoid smoking. Moreover, knowledge of the disease and 
regular mammogram tests can help in early diagnosis and 
treatment of the disease successfully resulting in a better 
quality of life for the victim [28].
Some forms of BC are easy to treat, whereas others are 
very difficult to treat, and occurrence is very prevalent. 
Currently, the primary forms of treatments include 
surgery followed by radiotherapy, chemotherapy and 
others such as palliative care for living well [11, 12]. Most 
commercial drugs are given, depending on the type of 
the BC that is being treated, where the cancer is located 
in the breast and types of breast cells affected [18,28-31]. 
Moreover, most of the commercial chemotherapeutic 
agents are not safe since they can kill normal healthy cells 
in the body especially at high doses [32]. As such, it is of 
paramount importance to look for new and safe forms 
of therapy. This is where the current research project 
comes in as an alternative form of safe treatment for BC 
using natural plant-based medicine either alone or in 
combination with a low dose of a commercial therapeutic 
anti-cancer agent combined with a high dose of the 
natural medicine or extract [18, 21].
Nature is a rich source of different types of natural medicinal 
and phytochemical products and for years scientists have 
been utilizing plant-based extracts and medicine to treat 
different types of cancers [21, 32]. Second, if single drug 
therapy is unable to treat the cancer, then it is important 
to employ combined therapy. Momordica charantia (MC) 
or bitter melon is a well-known plant which has been 
used for thousands of years as a natural medicine to treat 
several diseases including diabetes and cancer inflicting 
mankind [15, 33]. In two previous studies, we investigated 
the beneficial anticancer effects of a water-soluble extract
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of MC and α, β momorcharin, an isolated compound 
of MC, on several different cancer cell lines including 
1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1[16, 
17]. In light of these two previous studies, the current 
investigation was designed to ascertain a cost-effective 
and safe approach to treat BC using an ethanol soluble 
extract from M. charantia and compare with the effect of 
K-J, an isolated anticancer compound from the leaves 
of M. charantia and cisplatin, a commercial anticancer 
drug. The rationale of this study was to find a safe dose 
of BC ethanol soluble extract or K-J either alone or in 
combination with a low dose cisplatin to treat BC without 
killing healthy cells and where possible, the mechanism 
involved in BC cell death. The discussion will now focus on 
the main findings of this study and their relevance in BC 
therapy, especially for people in low-income countries in 
the world where they have to pay for healthcare [34].
The results of this study have demonstrated that the 
active anticancer ingredient(s) from the green succulent 
fruit in M. charantia is ethanol soluble and several studies 
have employed the same procedure in preparing the 
extracts which are highly efficacious in treating other 
diseases successfully including diabetes and cancer [15, 
19, 35]. In the present study, both low and high doses 
of the MC ethanol extract and K-J had no effect on the 
viability of healthy MCF-10A breast cell lines compared to 
cisplatin which killed over 60% of the cells after 24 hours 
of treatment. However, during 48 hours of treatment 
both doses of MC ethanol extract seemed to enhance cell 
viability slightly compared to K-J and cisplatin which 
killed MCF-10A cells with cisplatin being more toxic at 
both low and high doses compared to K-J at the higher 
concentration. Surprisingly, when cisplatin was combined 
with either MC ethanol extract or K-J, employing both 
doses, they had little or no significant effect on MCF-10A 
cell at both 24 and 48 hours of treatment. The results have 
clearly demonstrated that MC ethanol extract is safe to use 
in breast cancer therapy either alone or when combined 
with cisplatin since it does not kill the healthy cells even 
during 48 hours of treatment and rather reduce the toxic 
effects of cisplatin. In contrast, K-J alone, especially at 
high dose and longer treatment time, can kill the healthy 
cells. Interestingly, both MC ethanol extract and K-J seem 
to exert a protecting effect on the healthy cells against the 
adverse effect of cisplatin at both low and high doses at 
either 24 or 48 hours of treatment (Fig 3B/D). The current 
results are in agreement with two previous studies which 
revealed that that the water-soluble extract of MC had no 
cytotoxic effect on healthy cell lines [16, 17].
MCF-7 is a human breast cancer cell line was isolated 
in 1970 from a Caucasian woman with metastasis and it 
has estrogen, progesterone and glucocorticoid receptors 
and as such it is a well-established in vitro as a cell line 
model to study the effects of drugs on cell viability [36]. 
The results of this study have shown that either the MC 
ethanol extract or K-J had no significant effect at a low 
dose on MCF-7 cell viability at 24 hours of treatment. 
However, at a higher dose of 80 μg/mL and 24 hours of 
treatment, MC ethanol extract seemed to enhance MCF-
7 cell proliferation compared to K-J which reduced cell 
viability slightly (Fig 4A). When a high dose of cisplatin 
was combined with a high dose of either MC ethanol 
extract or K-J, they elicited more than 80% of cell death 
compared to untreated (control) cell at 24 hours (Fig 4B).
This effect was more or less the same as with cisplatin 
alone. However, during 48 hours of treatment with a low 
dose, either MC ethanol extract, K-J or cisplatin reduced 
cell viability by about 25%. At a high dose and during 48 
hours of treatment, K-J evoked only a small effect on cell 
death compared to the MC ethanol which induced about 
50% of cell and cisplatin which killed more than 90% of 
the cancer cells (Fig 4C). Interestingly, when either a low 
or a high dose of cisplatin was combined with a high dose of 
either MC ethanol extract or K-J for 48 hours, they evoked 
significant increases in MCF-7 cell death. Together, the 
main results from this part of the study revealed that a low 
dose of cisplatin combined with a high dose of either MC 
ethanol extract or K-J could elicit a synergistic effect on 
MCF-7 cell death after 48 hours of treatment. As such, the 
finding supports the hypothesis that combined application 
is a safer option for breast cancer therapy using a low dose 
of cisplatin and a high dose of MC ethanol extract or K-J. 
These results are in total agreement with related studies 
which show that bitter melon extract or juice alone can 
reduced the viability of MCF-7 and other cancer cell lines 
especially at a longer duration of treatment [19, 37].
Triple negative breast cancer (TNBC) represents almost 
10-20% of all breast cancers globally. This is due to the 
absence of estrogen and progesterone receptors and HER2 
proteins. TNBC cells do not respond to hormone therapy 
and as such, new and novel medicines are required to 
prevent their growth and subsequent death, but at the 
same time leaving healthy cells intact [38].
The results presented in figure 5 are highly significant 
and demonstrated that either the MC ethanol soluble 
extract, K-J or cisplatin either alone or in combination at 
low and high doses could kill MDAMB-231 (TNBC) cells by 
more than 90% after both 24 and 48 hours of treatment, 
making the MC ethanol extract and possible K-J at low 
concentration as very safe options in TNBC therapy. The 
present results are in agreement with a related study 
which employed 2% of bitter melon fruit juice (v/v) alone 
on both MCF-7 and MDAMB-231using 12, 24 and 48 
hours of treatment [19, 37, 39]. In addition to individual 
application of either MC ethanol extract, K-J or cisplatin 
like other studies, the present study also investigated 
combined therapy employing cisplatin with either MC 
ethanol extract or K-J.
It is now known that different anticancer drugs exert 
their killing effect via different cellular, subcellular 
and molecular mechanisms involving autophagy, 
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cellular calcium overloading, necrosis, microtubule 
disassembling, DNA damage, cell cycle arrest, suppression 
of c-Met signalling, mitochondrial cytochrome release 
and apoptosis [25, 26]. Programmed cell death or apoptosis 
occurs naturally in cells and many drugs kill cancer cells 
by this process. However, the underlying mechanisms of 
the growth inhibitory effects of M charantia extract and 
K-J in breast cancer cell remains poorly understood. In 
some cases, more than one processes occur, however, it is 
known that apoptosis is the dominant type involving the 
formation of multi-protein complexes that provide the 
molecular scaffolding for the activation of the initiator 
caspases including caspase -8 (extrinsic pathway), 
caspase -9 (intrinsic pathway) and caspase -3 (executioner 
caspase caspase-3 pathway [25, 26, 40, 41]. The results 
presented in figure 6 show that in both MDAMB-231 and 
MCF-7 cell lines, MC ethanol extract, K-J and cisplatin 
were able to increase caspase-3 activity by 82%, 75% and 
76%, respectively, indicating that all three agents are 
inducing breast cancer cell death through the activation 
of caspase-3 pathway. In two previous studies [17, 22], 
we had shown that a water soluble of M. charantia and α, 
β momorcharin, an isolated compound from bitter melon, 
were able to kill several cancer cell lines via apoptosis 
and cellular calcium overloading [16,17]. It is tempting 
to suggest that other intracellular signally pathways may 
be involved in MDAMB-231 and MCF-7 cell death but this 
warrants further experiments.
The results of this study have revealed that M. charantia is 
rich in a number of cations, especially sodium and calcium, 
proteins, phenols, antioxidants and other compounds. 
Other studies have reported more than 250 bioactive 
compounds with medicinal and nutritious characteristics 
in M. charantia [41-45]. The question which now arises 
is: how MC ethanol extract and K-J exerts their lethal 
effect when applied extracellularly to cells in vitro. Control 
experiments have shown that the dose of DMSO employed 
to dissolve either K-J, cisplatin or the MC extract had 
no effect on all three cell lines employed in this study. It 
is possible that either K-J or the active agent (s) in MC 
extract is lipid soluble and as such they can enter the cells 
very easily to activate different signaling pathways to 
elicit cell death via apoptosis [19, 21]. Currently, there is 
no evidence of receptor –mediated effect of extract of M. 
charantia or its isolated compounds.
Conclusion
The results of this study have clearly demonstrated 
that MC alcohol soluble extract had no effect on healthy 
human mammary epithelial MCF-10A cells as compared 
to cisplatin at all concentrations and K-J at a high dose. 
Moreover, either MC ethanol soluble extract, K-J or 
cisplatin either alone or in combination, using different 
doses, can evoke significant decrease in the viability of 
MCF-7 and MDA-MB-231 triple negative cancer cells in 
vitro. The cytotoxic effects of the three compounds were 
more pronounced in MDAMB-231 triple negative cancer 
cells as compared to MCF-7 cells. Moreover, all three 
compounds can exert their lethal anti-cancer effect on the 
cancer cells via damage of cell mitochondria body resulting 
in an elevation in the cellular mediator, caspase-3. It is 
concluded that it is safe to employ MC ethanol extract as 
a cytotoxic agent in breast cancer therapy especially in 
moderate concentration either alone or when combined 
with a low dose of a commercial anticancer drug such as 
cisplatin in order to enhance the efficacy of the drugs. 
Future studies would involve in vivo studies in breast 
cancer pre-clinical model to confirm these results.
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Test Samples Cell lysate Caspase-3 
5μg/ml








Reagent blank ----- ----- 90μl ----- 10 μl
Non-induced cells 5 μl ----- 85 μl ----- 10 μl
Non-induced cells+ 
inhibitor
5 μl ----- 75 μl 10 μl 10 μl
Induced cells 5 μl ----- 85 μl ----- 10 μl
Induced cells +
inhibitor
5 μl ----- 10 μl 10 μl
Caspase-3
positive control
----- 5 μl 85 μl ----- 10 μl
Caspase-3 positive 
control + inhibitor
----- 5 μl 75 μl 10 μl 10 μl
Table 1: Protocol of caspase-3 assay reaction scheme for 96 well plate micro-assay method
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Figure 1: (A) dark green alcohol extract solution and (B) M. charantia alcoholic solid extract.
Figure 2: Light microscope images of MCF-10A cells: (A) without treatment (control) and following treatment with 
8ug/mL of either (B) the alcohol soluble M. charantia extract, (C) K-J or (D) cisplatin. These images are typical of at 
least 3 different experiments.
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Figure 4: Dose -dependent cytotoxicity effect of the MC ethanol extract, K-J and cisplatin on MCF-7 breast cancer 
cells compared to untreated (control) cells for comparison. Fig 4A- each dose separately and Fig 4B- combined doses 
for 24 hours; Fig 4C- each dose separately and Fig 4D- combined doses for 48 hours. Data are mean ± SD, (n=3); 
**p<0.001*p<0.05 for MC ethanol extract, K-J and cisplatin in A, C and D compared to untreated (control) cells and 




























** ** ** 
* 
Figure 3: Dose-dependent cytotoxicity effect of the MC ethanol extract, K-J and cisplatin on healthy MCF-10A cell 
lines compared to untreated (control) cells for comparison. Fig 3A- each dose separately and Fig 3B- combined doses 
for 24 hours; Fig 3C- each dose separately and Fig 3D- combined doses for 48 hours. Data are mean ± SD, (n=3); 
*p<0.05, **p<0.001 for cisplatin in A and C compared to untreated control and for K-J in C compared to untreated 
(control) cells.
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* * * * * * 
Figure 6: Bar charts showing the caspase-3 activity (elevation) on MCF-7 and MDAMB-231 cell lines following 




























Figure 5: Dose -dependent cytotoxicity effect of the MC ethanol extract, K-J and cisplatin on MDAMB-231 triple 
negative breast cancer cell compared to untreated (control) cells for comparison. Fig 5A- each dose separately and Fig 
5B- combined doses for 24 h; Fig 5C- each dose separately and Fig 5D- combined doses for 48 hours. Data are mean ± 
SD, (n=3); **p<0.001 for MC ethanol extract, K-J and cisplatin in A, B, C and D compared to untreated (control) cells.
